Lung Cancer / Mesothelioma
Just last week I described in a prior post the news that a large trial of Nexavar (sorafenib) had been reported as negative in first line advanced NSCLC, and with some evidence of an increased risk of death on the novel agent in combination with chemo in the subset of patients with squamous cell […]
0 CommentsSeveral users on a recent thread have raised questions about whether exercise after surgery or chemo and radiation is harmful, beneficial, or has no effect on outcomes among people with lung cancer. Unfortunately, this field has so few answers that it’s easy to imagine doctors filling in the void with half-truths or less. I explained that I […]
3 CommentsHello again! Some of you may have wondered why any patient would choose to see an oncology social worker. I thought I would take this opportunity to explore the top reasons why patients come to see me in the first place. These are not in any particular order, except for the first one, so […]
4 CommentsI asked Dr. Carolyn Dressler, a terrific expert on nicotine addiction and smoking cessation, to write a general post on how to approach quitting. She’s actually a lung surgeon who also obtained a Masters in Public Health and now works as Branch Chief for the Tobacco Cessation and Prevention Program for the Arkansas State Governent. […]
1 CommentsGetting back to the issue of differences in side effects and efficacy of treatments based on differences in individuals and populations, let’s continue the story of how different populations appear to have significant differences in how the do on the same treatment regimen. In a recent prior post I described the SWOG-Japanese research collaboration […]
0 CommentsI’ll get back to the storyline of our growing understanding of the differences of individuals based on pharmacogenomics very soon. But I wanted to give people some breaking news that just came out. The first line ESCAPE trial of chemo with the anti-angiogenic and multi-kinase inhibitor nexavar (introductory post here) or placebo is apparently negative […]
8 CommentsWhile the differences in anticipated clinical benefits from EGFR tyrosine kinase inhibitors like tarceva and iressa are well known (summarized in prior post), less well appreciated is the potentially significant differences in results with garden variety standard chemotherapy. These differences are likely to be very relevant as the US has a harder time getting […]
0 CommentsThe issue of population-based differences in response to lung cancer treatments was essentially introduced with the EGFR inhibitors, so it’s appropriate to introduce racial differences overall with this work. Mention of more favorable results with EGFR inhibitors iressa and tarceva emerged with the earliest clinical studies and have since become a well established truism. […]
2 CommentsInfused throughout the website is a constant recognition that “patients are different”, but while we know this intuitively, we’re really not moved to a point of individualizing treatment on the basis of this. There are many lines of clinical research that are moving in that direction, and one of the key elements is pharmacogenomics, […]
2 CommentsMember Wendy asked me about a drug called picoplatin that I had heard of but really didn’t have much familiarity with. This gave me an occasion to flesh out some background on this agent, which is being developed as a potential therapy for patients previously treated for lung cancer. Developed by Poniard Pharmaceuticals in South […]
3 Comments
Posts
| Core Concepts
| Subject Archives
| Monthly Archives
| Resources
| 
Donate
| Forums
| GRACE Home
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2008 GRACE. All rights reserved.
